This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. (VRTX) slid 2.04% to $438.40 Monday, on what proved to be an all-around great trading session for the stock market, with the S&amp;P 500 Index rising 0.26% to 7,599.96 and the Dow Jones Industrial Average rising 0.09% to 51,078.88.
This was the stock's second consecutive day of losses.
Vertex Pharmaceuticals Inc. closed 13.69% short of its 52-week high of $507.92, which the company reached on March 10th.
The stock demonstrated a mixed performance when compared to some of its competitors Monday, as AbbVie Inc. (ABBV) fell 2.20% to $212.93, Krystal Biotech Inc. (KRYS) fell 3.54% to $298.10, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 1.89% to $7.77.
Trading volume (1.1 M) remained 144,257 below its 50-day average volume of 1.3 M.
Data source: Dow Jones Market Data, FactSet. Data compiled June 1, 2026.
This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
06-01-26 1638ET

VRTX

Vertex Pharmaceuticals (VRTX) shares fell 2.04% to $438.40, marking its second consecutive day of losses despite a broader market rally. The stock remains 13.69% below its 52-week high. While competitors like AbbVie and Krystal Biotech also declined, Vertex outperformed them slightly. Trading volume was below the 50-day average.

MarketWatch Automated

Vertex Pharma

S&P 500

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day